Pusztai L - Search Results

1

An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer.

Stemke-Hale K, Gonzalez-Angulo AM, Lluch A, Neve RM, Kuo WL, Davies M, Carey M, Hu Z, Guan Y, Sahin A, Symmans WF, Pusztai L, Nolden LK, Horlings H, Berns K, Hung MC, van de Vijver MJ, Valero V, Gray JW, Bernards R, Mills GB, Hennessy BT. Stemke-Hale K, et al. Among authors: pusztai l. Cancer Res. 2008 Aug 1;68(15):6084-91. doi: 10.1158/0008-5472.CAN-07-6854. Cancer Res. 2008. PMID: 18676830 Free PMC article.

2

Daily oral etoposide in patients with heavily pretreated metastatic breast cancer.

Pusztai L, Walters RS, Valero V, Theriault RL, Hortobagyi GN. Pusztai L, et al. Am J Clin Oncol. 1998 Oct;21(5):442-6. doi: 10.1097/00000421-199810000-00004. Am J Clin Oncol. 1998. PMID: 9781596 Clinical Trial.

3

Physiologic and pathologic drug resistance in ovarian carcinoma--a hypothesis based on a clonal progression model.

Pusztai L, Siddik ZH, Mills GB, Bast RC Jr. Pusztai L, et al. Acta Oncol. 1998;37(7-8):629-40. doi: 10.1080/028418698429964. Acta Oncol. 1998. PMID: 10050979 Review.

4

Relapse after complete response to anthracycline-based combination chemotherapy in metastatic breast cancer.

Pusztai L, Asmar L, Smith TL, Hortobagyi GN. Pusztai L, et al. Breast Cancer Res Treat. 1999 May;55(1):1-8. doi: 10.1023/a:1006161906667. Breast Cancer Res Treat. 1999. PMID: 10472774

5

Chemo-signal therapy, an emerging new approach to modify drug resistance in breast cancer.

Pusztai L, Esteva FJ, Cristofanilli M, Hung MC, Hortobagyi GN. Pusztai L, et al. Cancer Treat Rev. 1999 Oct;25(5):271-7. doi: 10.1053/ctrv.1999.0132. Cancer Treat Rev. 1999. PMID: 10544071 Review.

6

Chemotherapy of metastatic breast cancer: what to expect in 2001 and beyond.

Esteva FJ, Valero V, Pusztai L, Boehnke-Michaud L, Buzdar AU, Hortobagyi GN. Esteva FJ, et al. Among authors: pusztai l. Oncologist. 2001;6(2):133-46. doi: 10.1634/theoncologist.6-2-133. Oncologist. 2001. PMID: 11306725 Free article. Review.

7

Expression of erbB/HER receptors, heregulin and P38 in primary breast cancer using quantitative immunohistochemistry.

Esteva FJ, Hortobagyi GN, Sahin AA, Smith TL, Chin DM, Liang SY, Pusztai L, Buzdar AU, Bacus SS. Esteva FJ, et al. Among authors: pusztai l. Pathol Oncol Res. 2001;7(3):171-7. doi: 10.1007/BF03032345. Pathol Oncol Res. 2001. PMID: 11692142 Free article.

8

Factors predictive of outcome in patients with breast cancer refractory to neoadjuvant chemotherapy.

Buchholz TA, Hill BS, Tucker SL, Frye DK, Kuerer HM, Buzdar AU, McNeese MD, Singletary SE, Ueno NT, Pusztai L, Valero V, Hortobagyi GN. Buchholz TA, et al. Among authors: pusztai l. Cancer J. 2001 Sep-Oct;7(5):413-20. Cancer J. 2001. PMID: 11693900

9

Surgical conservation planning after neoadjuvant chemotherapy for stage II and operable stage III breast carcinoma.

Kuerer HM, Singletary SE, Buzdar AU, Ames FC, Valero V, Buchholz TA, Ross MI, Pusztai L, Hortobagyi GN, Hunt KK. Kuerer HM, et al. Among authors: pusztai l. Am J Surg. 2001 Dec;182(6):601-8. doi: 10.1016/s0002-9610(01)00793-0. Am J Surg. 2001. PMID: 11839324

10

Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer.

Esteva FJ, Valero V, Booser D, Guerra LT, Murray JL, Pusztai L, Cristofanilli M, Arun B, Esmaeli B, Fritsche HA, Sneige N, Smith TL, Hortobagyi GN. Esteva FJ, et al. Among authors: pusztai l. J Clin Oncol. 2002 Apr 1;20(7):1800-8. doi: 10.1200/JCO.2002.07.058. J Clin Oncol. 2002. PMID: 11919237 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

565 results

Search Page

Filters